Update on InnomarClinics

InnomarClinics remain open to our patients amidst coronavirus (COVID-19) concerns.

Learn more.

Insights

Innomar Strategies

Webinar: 2020 pan-Canadian Oncology Drug Review (pCODR) Updates

Innomar Strategies

September 2020

Manufacturers

Webinar: The Caregiver and Patient Support Programme

Innomar Strategies

Manufacturers

Webinar: Utilizing Real World Evidence Across the Product Life Cycle

Innomar Strategies

Manufacturers

Market Access: Negotiations

Innomar Strategies

Manufacturers

Market Access: Reimbursement

Innomar Strategies

Manufacturers

Market Access: Pricing

Innomar Strategies

Manufacturers

Time-to-treatment initiation (TTI) in community infusion clinics - decreasing wait times for Canadian oncology patients

Innomar Strategies

Manufacturers

Regulatory Services: Submission Filing

Quality, Regulatory & Safety

Manufacturers

Regulatory Services: Submission and Product Lifecycle Considerations

Quality, Regulatory & Safety

Manufacturers

Regulatory Services: How are products approved?

Quality, Regulatory & Safety

Manufacturers

Regulatory Services: Navigating Clinical Trial applications

Quality, Regulatory & Safety

Manufacturers

Commercializing in Canada: Quality Assurance and GMP Services

Innomar Strategies

Manufacturers

Commercializing in Canada: Regulatory Publishing and Submissions

Innomar Strategies

Manufacturers

Webinar: Health Canada’s Regulatory and Quality approach to addressing COVID-19 challenges

Innomar Strategies

Manufacturers

3PL & Importation: Cost savings through Innomar's scalable supply chain solutions.

Innomar Strategies

Manufacturers

3PL & Importation: Quality-assured, temperature-controlled and secure GMP-compliant facility.

Innomar Strategies

Manufacturers

3PL & Importation: Supporting your product commercialization through Importation

Innomar Strategies

Manufacturers

Why Canada: Leveraging our partnerships and relationships to assist in your launch strategy.

Sandra Anderson

Commercialization and Strategy

Manufacturers

Why Canada: How we help Pharmaceutical Manufacturers commercialize their products in Canada.

Sandra Anderson

Commercialization and Strategy

Manufacturers

Why Canada: Is Canada an attractive market for global pharmaceutical manufacturers?

Sandra Anderson

Commercialization and Strategy

Manufacturers

InnomarLive 2019: Commercializing in Canada

Innomar Strategies

Manufacturers

Insight Series: The Value of Real-World Evidence in Canadian Drug Commercialization – Part 1

Innomar Strategies

InnomarLive Summary: Healthcare Innovation

Innomar Strategies

Manufacturers

Insight Series: Value of Patient Support Programs for Specialty Medications in Canada

Innomar Strategies

Infographic: The Route to Market Access in Canada

Innomar Strategies

Infographic: The Road to Commercialization in Canada

Innomar Strategies

Insight Series: Biosimilars in Canada

Innomar Strategies

Drug Reimbursement in Canada

Innomar Strategies

Improved Health Outcomes in Patients Receiving Health Case Management

Innomar Strategies

Understanding the Journey of a Person with a Rare Disease

Innomar Strategies

Specialty pharmacies enhance patient outcomes [Pharmacy Practice Plus]

Jason Zabransky

Specialty Operations

Case Study: Patient-centric Care in Rare Disease

Innomar Strategies

Future of Patient Support Programs in Canada

Sandra Anderson

Commercialization and Strategy

Case Study: Discovering New Opportunities for Growth in a Niche Market

Innomar Strategies

Case Study: Leveraging Physician Relationships to Co-create Patient Support

Innomar Strategies

Case Study: Optimizing a Patient Support Program to Improve Therapy Adherence

Innomar Strategies

Support Programs Designed to Assist Patients and Their Families

Sandra Anderson

Commercialization and Strategy

Big Wins in Record Time for Gaining Market Access with Phase II Data

Innomar Strategies

Nurse-led Health Case Management

Innomar Strategies

InSight Industry Update Series